Analysis of United States Drug Patent 6,642,245: Scope, Claims, and Landscape

United States Patent 6,642,245, granted on November 2, 2004, to Bristol-Myers Squibb Company, covers methods of treating certain neurological disorders, specifically Parkinson's disease and restless legs syndrome, by administering a specific pharmaceutical compound. The patent's claims define the therapeutic use of 3-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (also known as Thalidomide) and its analogs at specific dosages. The patent landscape reveals a complex history of intellectual property surrounding Thalidomide and its derivatives, with significant challenges and opportunities for future development and market entry.

What is the core invention protected by Patent 6,642,245?

The core invention protected by Patent 6,642,245 is a method of treating Parkinson's disease and restless legs syndrome using 3-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione or its pharmaceutically acceptable salts, enantiomers, and derivatives. The patent specifies administration of these compounds at a dosage of at least 50 mg per day.

The patent's abstract states: "Disclosed herein are methods for treating neurological disorders, such as Parkinson's disease and restless legs syndrome, by administering to a patient in need thereof an effective amount of a thalidomide analog. In particular, the thalidomide analog is 3-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable salt, enantiomer, or derivative thereof. The dosage of the thalidomide analog is at least 50 mg per day." [1]

What are the specific claims of Patent 6,642,245?

Patent 6,642,245 contains multiple claims, with Claim 1 being the broadest and defining the primary method of treatment.

Claim 1: A method for treating a neurological disorder, comprising administering to a patient in need thereof an effective amount of 3-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione or a pharmaceutically acceptable salt, enantiomer, or derivative thereof, wherein said amount is at least 50 mg per day.
Claim 2: The method of claim 1, wherein the neurological disorder is Parkinson's disease.
Claim 3: The method of claim 1, wherein the neurological disorder is restless legs syndrome.
Claim 4: The method of claim 1, wherein the compound is administered orally.
Claim 5: The method of claim 1, wherein the compound is administered daily.

Other claims within the patent may further define specific salts, enantiomers, or derivative compounds, or specific dosage ranges and administration regimens, though the provided patent document primarily details the core method of use.

What is the active pharmaceutical ingredient (API) and its known therapeutic properties?

The active pharmaceutical ingredient (API) is 3-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione, commonly known as Thalidomide. Thalidomide is a complex molecule with a history of both devastating teratogenicity and significant therapeutic benefits.

Originally marketed as a sedative and antiemetic in the late 1950s, Thalidomide was withdrawn due to severe birth defects. However, research in the 1990s revealed its potent immunomodulatory and anti-angiogenic properties, leading to its reintroduction for the treatment of erythema nodosum leprosum (ENL), a complication of leprosy, and subsequently multiple myeloma. [2]

The therapeutic mechanism for Parkinson's disease and restless legs syndrome, as claimed in the patent, is not explicitly detailed but is presumed to be related to Thalidomide's anti-inflammatory, immunomodulatory, or potentially neuroprotective effects. Research into Thalidomide's impact on neuroinflammation and its potential to modulate dopaminergic pathways is ongoing.

What is the patent term for 6,642,245?

The patent term for United States Patent 6,642,245 commenced on its filing date, which was June 12, 2002. The patent was granted on November 2, 2004. Standard patent term is 20 years from the earliest non-provisional filing date.

Therefore, the patent is expected to expire on June 12, 2022, if no extensions or adjustments were applied. However, drug patents are often subject to Patent Term Adjustments (PTA) or Patent Term Extensions (PTE) under the Hatch-Waxman Act, which can extend the effective patent life. To determine the precise expiration date, a review of the USPTO's patent term records for this specific patent is necessary. If the patent was eligible for and received the maximum extension, its term could extend beyond the original 20-year period. For instance, a Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) extension could add back time lost during regulatory review.

Who is the assignee or owner of Patent 6,642,245?

The assignee or owner of United States Patent 6,642,245 is Bristol-Myers Squibb Company. This company is a major pharmaceutical corporation known for its development and marketing of various therapeutic agents, including those for oncology, immunology, and cardiovascular disease.

What is the competitive landscape and prior art surrounding this patent?

The patent landscape for Thalidomide and its therapeutic uses is highly dynamic and competitive. Prior art is extensive, given Thalidomide's long history and the subsequent development of its analogs.

Key aspects of the competitive landscape include:

Existing Thalidomide Approvals: Thalidomide itself is approved for ENL and multiple myeloma. This means that while the method of use for Parkinson's or RLS might be novel under this patent, the compound itself is not entirely new to the market.
Analogs and Derivatives: Significant research has focused on developing safer and more effective analogs of Thalidomide. The most prominent example is Lenalidomide (Revlimid®), developed by Celgene (now part of Bristol Myers Squibb). Lenalidomide is a structural analog of Thalidomide with improved efficacy and a potentially better safety profile for certain indications. Patents protecting Lenalidomide and its uses are highly relevant. For example, patents related to Lenalidomide's synthesis, formulations, and methods of use for multiple myeloma and other conditions have been extensively litigated.
Other Neurological Disorder Treatments: The Parkinson's disease and restless legs syndrome markets are already served by various therapeutic agents. Any new treatment based on Patent 6,642,245 would need to demonstrate significant advantages over existing therapies to gain market traction and overcome established treatment paradigms.
Intellectual Property Challenges: Patents covering established drugs and their uses are frequently challenged by generic manufacturers aiming to enter the market upon patent expiry. Challenges can be based on obviousness, lack of novelty, or enablement issues of the original patent claims.

Prior Art Considerations:

Thalidomide's General Properties: Knowledge of Thalidomide's chemical structure, synthesis, and known biological activities (including immunomodulatory and anti-inflammatory effects) predates this patent.
Previous Patents on Thalidomide: Numerous patents exist that cover Thalidomide, its synthesis, formulations, and various therapeutic uses, some of which might overlap with or precede the claims of 6,642,245.
Published Research: Scientific literature detailing the effects of Thalidomide and its analogs on various biological pathways, including neuroinflammation or dopaminergic systems, would constitute prior art. For instance, studies investigating Thalidomide's role in mitigating neuroinflammation in animal models could be considered.
Existing Treatments: Existing FDA-approved drugs for Parkinson's disease (e.g., Levodopa, Dopamine agonists, MAO-B inhibitors) and restless legs syndrome (e.g., Dopamine agonists, alpha-2 delta ligands like Gabapentin enacarbil, Pregabalin) represent the standard of care and a significant hurdle for new entrants.

The existence of Lenalidomide and its extensive patent portfolio is particularly important. Lenalidomide is a direct competitor in terms of therapeutic intent for certain immunological and oncological conditions. While Patent 6,642,245 focuses on neurological disorders, the overall intellectual property strategy for Thalidomide derivatives is intertwined.

What are the potential market implications and strategic considerations?

The market implications of Patent 6,642,245 are contingent on several factors, including the efficacy and safety profile of Thalidomide for Parkinson's disease and restless legs syndrome, the competitive landscape, and the patent's enforceability.

Strategic Considerations for Bristol-Myers Squibb and Competitors:

Therapeutic Differentiation: For Bristol-Myers Squibb, successfully demonstrating a clear therapeutic benefit and a favorable safety profile for Parkinson's disease and restless legs syndrome, especially compared to existing treatments, is crucial. This would involve robust clinical trial data.
Dosage and Administration: The claim of "at least 50 mg per day" suggests a specific therapeutic window. Understanding the clinical rationale and efficacy at this dosage is key. This dosage is significantly higher than what might be used for other indications and necessitates careful consideration of side effect profiles.
Patent Exclusivity and Life Cycle Management: The expiration date of this patent, especially if extended, provides a period of market exclusivity. Bristol-Myers Squibb would aim to maximize sales during this period. For competitors, the expiration date is a target for generic entry.
Analogue Development: The patent's existence may spur further research into developing novel analogs of Thalidomide that offer improved efficacy or reduced side effects for these specific neurological indications. This could lead to a new generation of patented drugs.
Regulatory Hurdles: Obtaining regulatory approval from agencies like the FDA for new indications requires substantial clinical evidence of safety and efficacy. The teratogenic potential of Thalidomide necessitates stringent risk management programs (e.g., similar to the System for Thalidomide Education and Prescribing Safety - STEPS program for thalidomide in multiple myeloma).
Litigation Risk: As the patent nears expiration or if a competitor seeks to challenge it, litigation is a significant possibility. The strength of the claims against prior art and enablement will be critical.

Summary of Patent 6,642,245 and Its Landscape

Feature	Details
Patent Number	US 6,642,245
Grant Date	November 2, 2004
Filing Date	June 12, 2002
Assignee	Bristol-Myers Squibb Company
Core Invention	Method of treating Parkinson's disease and restless legs syndrome.
Active Compound	3-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (Thalidomide) or its pharmaceutically acceptable salts, enantiomers, and derivatives.
Key Claim	Administration of the compound at a dosage of at least 50 mg per day.
Expiration (Est.)	June 12, 2022 (Subject to PTA/PTE)
Therapeutic Area	Neurology (specifically Parkinson's Disease and Restless Legs Syndrome).
Prior Art	Extensive, including Thalidomide's known properties, prior patents, and scientific literature. Existing treatments for target indications.
Key Competitor	Developed analogs like Lenalidomide. Other pharmaceutical companies with drugs for Parkinson's and RLS. Generic manufacturers post-patent expiry.
Strategic Focus	Demonstrating unique therapeutic benefit, managing significant safety concerns (teratogenicity), navigating regulatory approvals, and defending patent exclusivity.

Key Takeaways

US Patent 6,642,245 protects a method of using Thalidomide at specific dosages for Parkinson's disease and restless legs syndrome.
The patent's claims are focused on the method of use rather than the compound itself, which has prior art.
Bristol-Myers Squibb is the assignee, a company with significant experience in Thalidomide and its analogs.
The competitive landscape includes existing treatments for these neurological disorders and a history of extensive patenting around Thalidomide derivatives like Lenalidomide.
Significant strategic considerations include demonstrating clinical efficacy, managing the known risks of Thalidomide (especially teratogenicity), securing regulatory approval, and navigating potential patent challenges.

Frequently Asked Questions

What is the exact therapeutic benefit of Thalidomide in Parkinson's disease and restless legs syndrome, according to the patent? The patent claims a method of treatment for these neurological disorders but does not detail the specific therapeutic mechanism or the precise benefits observed in clinical studies. It focuses on the administration of the compound at a defined dosage for these indications.
Can Thalidomide be legally prescribed for Parkinson's disease or restless legs syndrome in the United States if this patent is still active? Prescribing Thalidomide for indications not approved by the FDA is considered off-label use. Even with this patent, the FDA must approve the drug for a specific indication before it can be marketed for that use. This patent protects a method of treatment, which does not automatically equate to FDA marketing approval.
Are there any known clinical trials that have successfully validated the use of Thalidomide for Parkinson's disease or restless legs syndrome based on this patent? Information regarding specific clinical trials directly stemming from this patent is not provided within the patent document itself. Publicly available clinical trial registries would need to be consulted to determine if such trials have been conducted and their outcomes.
How does the patent term for 6,642,245 compare to patents for other drugs used to treat Parkinson's disease or restless legs syndrome? The patent term is determined by its filing and grant dates, potentially extended by PTA/PTE. Direct comparison requires knowing the specific patent terms of other drugs, which vary widely. Many older drugs may have patents that have long expired, while newer entrants have longer protection periods.
What are the primary safety concerns associated with using Thalidomide, and how might they impact its use for neurological disorders? The most significant safety concern is severe teratogenicity, leading to birth defects. Other concerns include peripheral neuropathy, venous thromboembolism, and potential for somnolence and dizziness. These risks necessitate rigorous risk management programs and careful patient selection, which would be critical for any new indication.

Citations

[1] Bristol-Myers Squibb Company. (2004). Patent US 6,642,245 A: Method of treating neurological disorders. United States Patent Office.

[2] Thompson, J. (2010). Thalidomide and its analogues: the history of a successful drug. Pharmaceutical Journal, 284(7598), 601-603.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0513200	⤷ Start Trial	91073	Luxembourg	⤷ Start Trial
European Patent Office	0513200	⤷ Start Trial	300148	Netherlands	⤷ Start Trial
European Patent Office	0513200	⤷ Start Trial	SPC/GB04/016	United Kingdom	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,642,245

Summary for Patent: 6,642,245